Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers

Background: BRAF V600 mutations are the epitome of targeted therapy. However, not much is known about non-V600 mutations. Using the new data infrastructure of the Swiss Personalized Oncology project of the Swiss Personalized Health Network (SPHN), we evaluated the fate of patients with cancer with n...

Full description

Bibliographic Details

Published in:	ESMO Real World Data and Digital Oncology
Main Authors:	S. Pradervand, N. Freundler, B. Gosztonyi, L. Roncoroni, R. Achermann, T. Schwenk, G. de Fraipont, J. Garessus, S. Haefliger, A.B. Leichtle, M.K. Kiessling, T. Mueller-Focke, F.S. Krebs, V. Zoete, P. Tsantoulis, O. Michielin, C. Britschgi, A. Wicki
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Subjects:	BRAF mutations precision oncology personalized treatment Swiss Personalized Health Network (SPHN)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2949820124000535